High dose chemotherapy (HDCT) plus autologous stem cell transplantation (ASCT) in multiple sclerosis (Ms) patients: Follow-up results of a prospective multicenter study

被引：0
|
作者：
Shevchenko, Y. L.
Novik, A. A.
Kuznetcov, A. N.
Afanasiev, B. V.
Lisukov, I. A.
Rykavicin, O. A.
Myasnikov, A. A.
Ionova, T. I.
Melnichenko, V. J.
Fedorenko, D. A.
Kryglina, R. V.
Kishtovich, A. V.
Ivanov, R. A.
Gorodokin, G. J.
机构：
[1] Natl Pirogov Med Surg Ctr, Moscow, Russia
[2] Pavlov State Med Univ, St Petersburg, Russia
[3] Russian Acad Sci, Inst Clin Immunol, Siberian Branch, Novosibirsk, Russia
[4] Burdenko Cent Mil Hosp, Moscow, Russia
[5] Republ Hosp, Petrozavodsk, Russia
[6] Multinatl Ctr Qual Life Res, St Petersburg, Russia
[7] New Jersey Ctr Qual Life & Hlth Outcome Res, New Jersey, NJ USA
来源：
EXPERIMENTAL HEMATOLOGY | 2007年 / 35卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] Multicenter experience of high dose chemotherapy (HDCT) plus Autologous stem cell transplantation (ASCT) in multiple sclerosis (MS) patients.
    Shevchenko, Yury L.
    Novik, Andrei A.
    Kuznetcov, AlexeyN.
    Afanasiev, Boris V.
    Lisukov, Igor A.
    Rykavicin, Oleg A.
    Myasnikov, Alexandr A.
    Lonova, Tatiana I.
    Shamanski, Sergey V.
    Kulagin, Andrey D.
    Malysheva, Olga A.
    Baziy, Nikolay I.
    Melnichenko, Vladimir Y.
    Fedorenko, Denis A.
    Vereschagina, Inna V.
    Zdorov, Andrey E.
    Kishtovich, Anton V.
    Ivanov, Roman A.
    Fedotov, Yury N.
    Gorodokin, Gary I.
    BLOOD, 2006, 108 (11) : 875A - 875A
  • [2] High-dose chemotherapy plus autologous stem cell transplantation in multiple sclerosis patients: follow-up results of a prospective multicentre study
    Shevchenko, J.
    Novik, A.
    Kuznetcov, A.
    Afanasiev, B.
    Lisukov, I.
    Rykavicin, O.
    Myasnikov, A.
    Ionova, T.
    Shamanski, S.
    Kulagin, A.
    Malysheva, O.
    Baziy, N.
    Melnichenko, V.
    Fedorenko, D.
    Zdorov, A.
    Kishtovich, A.
    Ivanov, R.
    Fedotov, J.
    Gorodokin, G.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S215 - S216
  • [3] CLINICAL AND QOL RESPONSE IN MULTIPLE SCLEROSIS (MS) PATIENTS AFTER HIGH DOSE CHEMOTHERAPY (HDCT) plus AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
    Ionova, T. I.
    Afanasiev, B. V.
    Fedotov, Y. N.
    Fedorenko, D. A.
    Kishtovich, A. V.
    Vereschagina, I. V.
    Novik, A. A.
    Gorodokin, G. I.
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2083 - 2083
  • [4] Long-term follow-up in patients with multiple sclerosis (MS) after high dose chemotherapy (HDCT)+/-autologous stem cell transplantation (ASCT): The Russian experience.
    Novik, AA
    Ionova, TI
    Lesukov, IA
    Kulagin, AD
    Malysheva, AN
    Rukavitcin, OA
    Shamanski, SV
    Bisaga, GN
    Melnichenko, VY
    Voloshin, SV
    Kishtovich, AV
    Osipova, NE
    BLOOD, 2003, 102 (11) : 480B - 481B
  • [5] Treatment outcomes in multiple sclerosis (MS) patients after high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT): Longterm follow-up.
    Slievchenko, Y. L.
    Novik, A. A.
    Afanasiev, B. V.
    Lisukov, I. A.
    Rykavicin, O. A.
    Shamanski, S. V.
    Ionova, T. I.
    Kulagin, A. D.
    Malysheva, O. A.
    Bisaga, G. N.
    Baziy, N. I.
    Melnichenko, V. Y.
    Fedorenko, D. A.
    Vereschagina, I. V.
    Kishtovich, A. V.
    Fedotov, Y. N.
    Gorodokin, N.
    Ivanov, R. A.
    CYTOTHERAPY, 2006, 8
  • [6] Clinical and quality of life outcomes in patients with multiple sclerosis (MS) after high dose chemotherapy(HDCT) plus autologous stem cell transplantation (ASCT).
    Shevchenko, YL
    Novik, AA
    Afanasiev, BV
    Lisukov, IA
    Fedotov, YN
    Ionova, IT
    Kulagin, AD
    Malysheva, OA
    Bisaga, GN
    Melnichenko, VY
    Chelombit, LV
    Voloshin, SV
    Fedorenko, DA
    Vereschagina, IV
    Kishtovich, AV
    BLOOD, 2004, 104 (11) : 519A - 519A
  • [7] Treatment outcomes in multiple sclerosis (MS) patients after early, conventional and salvage high dose chemotherapy (HDCT) plus autologous stem cell transplantation (ASCT).
    Shevchenko, YL
    Novik, AA
    Afanasiev, BV
    Lisukov, IA
    Ionova, TI
    Kulagin, AD
    Malysheva, OA
    Bisaga, GN
    Melnichenko, VJ
    Voloshin, SV
    Fedorenko, DA
    Vereschagina, IV
    Kishtovich, AV
    Fedotov, YN
    Gorodokin, GI
    BLOOD, 2005, 106 (11) : 454B - 454B
  • [8] Quality of life as an important outcome of high-dose therapy plus autologous stem cell transplantation (HDCT plus ASCT) in multiple sclerosis patients
    Shevchenko, Y
    Novik, A
    Ionova, T
    Lesukov, I
    Kulagin, A
    Malysheva, O
    Melnichenko, V
    Bisaga, G
    Chelombit, L
    Kishtovich, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S213 - S213
  • [9] Long-term follow-up of 100 patients undergoing high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for Hodgkin's disease (HD).
    Forrest, DL
    Nevill, TJ
    Connors, JM
    Shepherd, JD
    Nantel, SH
    Sutherland, HJ
    Hogge, DE
    Toze, CL
    Barnett, MJ
    BLOOD, 1997, 90 (10) : 2636 - 2636
  • [10] Treatment outcomes in multiple sclerosis patients after high-dose chemotherapy plus autologous stem cell transplantation: long-term follow-up
    Shevchenko, YL
    Novik, AA
    Afanasiev, BV
    Lisukov, IA
    Rykavicin, OA
    Shamanski, SV
    Ionova, TI
    Kulagin, AD
    Malysheva, OA
    Bisaga, GN
    Baziy, NI
    Melnichenko, VY
    Fedorenko, DA
    Vereschagina, IV
    Kishtovich, AV
    Fedotov, YN
    Gorodokin, G
    BONE MARROW TRANSPLANTATION, 2006, 37 : S131 - S131
12345